MA46436A - Compositions comprenant de la relaxine et leurs méthodes d'utilisation - Google Patents

Compositions comprenant de la relaxine et leurs méthodes d'utilisation

Info

Publication number
MA46436A
MA46436A MA046436A MA46436A MA46436A MA 46436 A MA46436 A MA 46436A MA 046436 A MA046436 A MA 046436A MA 46436 A MA46436 A MA 46436A MA 46436 A MA46436 A MA 46436A
Authority
MA
Morocco
Prior art keywords
methods
compositions including
including relaxin
relaxin
compositions
Prior art date
Application number
MA046436A
Other languages
English (en)
Inventor
Mark Grinstaff
Ara Nazarian
Edward Rodriguez
Original Assignee
Beth Israel Deaconess Medical Ct Inc
Univ Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Ct Inc, Univ Boston filed Critical Beth Israel Deaconess Medical Ct Inc
Publication of MA46436A publication Critical patent/MA46436A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2221Relaxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M3/00Medical syringes, e.g. enemata; Irrigators
    • A61M3/005Medical syringes, e.g. enemata; Irrigators comprising means for injection of two or more media, e.g. by mixing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/07Proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA046436A 2016-10-07 2017-10-09 Compositions comprenant de la relaxine et leurs méthodes d'utilisation MA46436A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662405795P 2016-10-07 2016-10-07

Publications (1)

Publication Number Publication Date
MA46436A true MA46436A (fr) 2019-08-14

Family

ID=60186382

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046436A MA46436A (fr) 2016-10-07 2017-10-09 Compositions comprenant de la relaxine et leurs méthodes d'utilisation

Country Status (7)

Country Link
US (2) US11723957B2 (fr)
EP (2) EP3522911B1 (fr)
AU (2) AU2017339536B2 (fr)
CA (1) CA3078452A1 (fr)
DK (1) DK3522911T3 (fr)
MA (1) MA46436A (fr)
WO (1) WO2018068047A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102533456B1 (ko) 2016-05-18 2023-05-17 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
WO2021237061A1 (fr) * 2020-05-22 2021-11-25 Trustees Of Boston University Méthodes et compositions pour le traitement d'une maladie fibrotique
KR20240110824A (ko) 2021-11-11 2024-07-16 테크토닉 세러퓨틱스 인코포레이티드 릴랙신-2 융합 단백질 유사체 및 이의 사용 방법
IL324680A (en) 2023-05-18 2026-01-01 Tectonic Operating Company Inc Relaxin-2 fusion protein analogs and methods of using them

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2051375C (fr) 1989-05-04 2000-09-12 Dennis J. Henner Procede et compositions pour l'isolement de la relaxine humaine
DE69233069T2 (de) * 1991-03-15 2003-11-27 Amgen Inc., Thousand Oaks Pegylation von polypeptiden
US6251863B1 (en) * 1998-09-08 2001-06-26 Samuel K. Yue Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin
ITFI20030328A1 (it) * 2003-12-24 2005-06-25 Mario Bigazzi Uso della relaxina come adiuvante nella differenziazione
US20080269762A1 (en) * 2007-04-25 2008-10-30 Biomet Manufacturing Corp. Method and device for repair of cartilage defects
EP3572091B1 (fr) * 2010-08-17 2023-12-13 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US8404268B2 (en) 2010-10-26 2013-03-26 Kyphon Sarl Locally targeted anti-fibrotic agents and methods of use
EP2755691B1 (fr) * 2011-09-07 2018-08-22 Prolynx LLC Hydrogels à réticulation biodégradable
WO2015067791A1 (fr) * 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Promédicaments à bae de relaxine
UA123432C2 (uk) * 2014-07-30 2021-04-07 Нджм Біофармасьютікалз, Інк. Димер та спосіб його застосування для лікування метаболічних розладів
PT3387019T (pt) * 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso

Also Published As

Publication number Publication date
US11723957B2 (en) 2023-08-15
US20190282665A1 (en) 2019-09-19
WO2018068047A1 (fr) 2018-04-12
AU2017339536B2 (en) 2024-12-19
US20240173383A1 (en) 2024-05-30
DK3522911T3 (da) 2022-03-07
AU2017339536A1 (en) 2019-05-23
WO2018068047A8 (fr) 2019-03-21
AU2025202009A9 (en) 2025-04-17
AU2025202009A1 (en) 2025-04-10
EP4056196A1 (fr) 2022-09-14
EP3522911B1 (fr) 2021-12-08
EP3522911A1 (fr) 2019-08-14
CA3078452A1 (fr) 2018-04-12

Similar Documents

Publication Publication Date Title
EP3383430A4 (fr) Anticorps et leurs méthodes d'utilisation
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
EP3319611A4 (fr) Oxystérols et leurs méthodes d'utilisation
EP3700527A4 (fr) Inhibiteurs de papd5 et leurs méthodes d'utilisation
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
EP3436022A4 (fr) Oxystérols et leurs méthodes d'utilisation
EP3368016A4 (fr) Polysaccharides réduits et oxydés et leurs méthodes d'utilisation
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
EP3525583A4 (fr) Anticorps anti-c1s et leurs méthodes d'utilisation
EP3463381A4 (fr) Dérivés nucléotidiques et leurs méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA48595A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
MA43284A (fr) Composés et leurs méthodes d'utilisation
EP3356381A4 (fr) Dérivés nucléotidiques et leurs méthodes d'utilisation
EP3337517A4 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
EP3684369A4 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
EP3634390A4 (fr) Compositions antimicrobiennes comprenant des cannabinoïdes et leurs méthodes d'utilisation
MA42409A (fr) Oxystérols et leurs procédés d'utilisation
MA54851A (fr) Oxystérols et leurs procédés d'utilisation
EP3419656A4 (fr) Compositions de néoantigène et leurs méthodes d'utilisation en immuno-oncothérapie